Andrew Putnam, MD
Cardiovascular Disease · Crown Point, INNPI 1649616582
Payments from drug & device makers
Across 265 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Amgen$1K
- Abbott$1K
- Novartis$962
- Heartflow, Inc.$507
- Boehringer Ingelheim$491
- plus $2K from 18 others
What the payments were for
- Travel & lodging$6638%
- Food & beverage$7,35790%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $1,431 |
| Amgen | 45 | $1,225 |
| Abbott | 18 | $1,042 |
| Novartis | 63 | $962 |
| Heartflow, Inc. | 6 | $507 |
| Boehringer Ingelheim | 17 | $491 |
| Johnson & Johnson | 20 | $383 |
| Edwards Lifesciences | 5 | $317 |
| AstraZeneca | 13 | $295 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $251 |
| Lantheus Medical Imaging, Inc. | 9 | $192 |
| Vifor Pharma, Inc. | 5 | $181 |
| Regeneron Healthcare Solutions, Inc. | 5 | $180 |
| Merck | 7 | $156 |
| Pfizer | 7 | $134 |
| Bridgebio Pharma, Inc. | 1 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $85 |
| Novo Nordisk | 2 | $43 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Cvrx, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $12 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$1,015
- FFRct$377
- CARDIOMEMS$311
- SAPIEN 3 Ultra RESILIA$232
- EnSite X$145
- HeartMate 3 Left Ventricular Assist Device$140
- Attruby$124
- JARDIANCE$114
- Repatha$110
- Veltassa$106
- GENERAL - STRUCTURAL HEART$102
How this compares
$8,134 in reported general payments places this provider in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 508 | $626,506 |
| XareltoRivaroxaban | 248 | $274,402 |
| Repatha SureclickEvolocumab | 177 | $221,777 |
| EntrestoSacubitril/Valsartan | 163 | $200,152 |
| JardianceEmpagliflozin | 93 | $152,397 |
| FarxigaDapagliflozin Propanediol | 31 | $39,945 |
| BrilintaTicagrelor | 27 | $23,877 |
| MultaqDronedarone Hcl | 13 | $11,668 |
| Atorvastatin Calcium | 1,252 | $10,257 |
| VascepaIcosapent Ethyl | 11 | $9,849 |
| EdarbiAzilsartan Medoxomil | 11 | $7,323 |
| Icosapent Ethyl | 14 | $6,599 |
| Amiodarone Hcl | 138 | $6,338 |
| DapagliflozinDapagliflozin Propanediol | 12 | $6,090 |
| Metoprolol Succinate | 442 | $6,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $134 | $626,506508 claims |
| Johnson & JohnsonXarelto | $383 | $274,402248 claims |
| NovartisEntresto | $962 | $200,152163 claims |
| Boehringer IngelheimJardiance | $491 | $152,39793 claims |
| AstraZenecaFarxiga, Brilinta | $295 | $63,82358 claims |
| Sanofi-aventis U.S. LLCMultaq | $31 | $11,66813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Crown Point
- Manoj DuggalCrown Point$181K
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.